{"log_id": 2672086874551571055, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.405536, "min": 0.405536}, "location": {"width": 22, "top": 80, "height": 19, "left": 1138}, "words": " Mid"}, {"probability": {"variance": 0, "average": 0.998843, "min": 0.998843}, "location": {"width": 25, "top": 108, "height": 22, "left": 1137}, "words": "证"}, {"probability": {"variance": 0.002558, "average": 0.951008, "min": 0.882038}, "location": {"width": 125, "top": 231, "height": 27, "left": 253}, "words": "抗HIV活性"}, {"probability": {"variance": 0.00454, "average": 0.98731, "min": 0.588758}, "location": {"width": 776, "top": 274, "height": 32, "left": 253}, "words": "抗病毒活性:在淋巴母细胞系、原代单核细胞/巨噬细胞和外周血淋巴细胞中评估"}, {"probability": {"variance": 0.00429, "average": 0.978584, "min": 0.691403}, "location": {"width": 807, "top": 315, "height": 36, "left": 213}, "words": "了替诺福韦抗实验室和临床分离HIV-1抗病毒活性。替诺福韦的EC50(50%有效浓"}, {"probability": {"variance": 0.001157, "average": 0.9897, "min": 0.787499}, "location": {"width": 817, "top": 362, "height": 31, "left": 212}, "words": "度)值在0.04μM至8.5μM之间。在替诺福韦与核苷反转录酶抑制剂(阿巴卡韦、去"}, {"probability": {"variance": 0, "average": 0.999344, "min": 0.997922}, "location": {"width": 810, "top": 404, "height": 34, "left": 211}, "words": "羟基苷、拉米夫定、司他夫定、扎西他滨、齐多夫定)、非核苷反转录酶抑制剂(地"}, {"probability": {"variance": 1e-05, "average": 0.998708, "min": 0.981341}, "location": {"width": 790, "top": 449, "height": 32, "left": 210}, "words": "拉韦定、依非韦伦、奈韦拉平)、蛋白酶抑制剂(安普那韦、茚地那韦、奈非那韦"}, {"probability": {"variance": 9.8e-05, "average": 0.996434, "min": 0.940312}, "location": {"width": 816, "top": 491, "height": 35, "left": 210}, "words": "利托那韦、沙奎那韦)联合用药的研究中,替诺福韦没有拮抗作用。在细胞培养中替"}, {"probability": {"variance": 0.008306, "average": 0.965174, "min": 0.573795}, "location": {"width": 794, "top": 536, "height": 34, "left": 209}, "words": "诺福韦对HIV-1的亚型A、B、C、D、E、F、G、O有抗病毒活性(EC50值范围为"}, {"probability": {"variance": 0.00825, "average": 0.964726, "min": 0.46825}, "location": {"width": 776, "top": 580, "height": 32, "left": 209}, "words": "05μM至2.2μM),对HIV-2有因病毒株而异的活性(ECso值范围为:1.6μM至"}, {"probability": {"variance": 0.007649, "average": 0.914709, "min": 0.778118}, "location": {"width": 71, "top": 627, "height": 21, "left": 211}, "words": "5.5μM)"}, {"probability": {"variance": 0.00194, "average": 0.986749, "min": 0.760128}, "location": {"width": 775, "top": 666, "height": 35, "left": 251}, "words": "耐药性:在细胞培养中挑选出了对替诺福韦敏感性降低的HIV-1分离病毒株。这"}, {"probability": {"variance": 8.4e-05, "average": 0.996293, "min": 0.953508}, "location": {"width": 697, "top": 708, "height": 35, "left": 208}, "words": "些病毒的反转录酶都出现K65R突变,对替诺福韦的敏感性降低了2-4倍"}, {"probability": {"variance": 0.001447, "average": 0.991883, "min": 0.767344}, "location": {"width": 756, "top": 751, "height": 36, "left": 254}, "words": "在对未接受过治疗的受试者进行的研究903中(富马酸替诺福韦二吡呋酯+拉米"}, {"probability": {"variance": 2.3e-05, "average": 0.997123, "min": 0.978004}, "location": {"width": 802, "top": 795, "height": 34, "left": 210}, "words": "夫定+依非韦伦与司他夫定+拉米夫定+依非韦伦),对144周内病毒学失败受试者中"}, {"probability": {"variance": 1e-05, "average": 0.998283, "min": 0.982377}, "location": {"width": 821, "top": 837, "height": 37, "left": 208}, "words": "分离的病毒株进行了基因分析结果显示与依非韦伦和拉米夫定耐药有关的突变最为常"}, {"probability": {"variance": 5.2e-05, "average": 0.996945, "min": 0.960021}, "location": {"width": 819, "top": 881, "height": 36, "left": 208}, "words": "见,两个治疗组之间没有差异。在所分析的患者分离病毒株中,富马酸替诺福韦二吡"}, {"probability": {"variance": 0.003478, "average": 0.986073, "min": 0.611924}, "location": {"width": 800, "top": 925, "height": 36, "left": 209}, "words": "呋酯组中K65R突变的发生率为8147(17%),司他夫定组为249(4%)。富马酸"}, {"probability": {"variance": 0.000278, "average": 0.995035, "min": 0.898163}, "location": {"width": 802, "top": 968, "height": 36, "left": 207}, "words": "替诺福韦二吡呋酯组144周内病毒出现K65R的8名受试者中,有7名发生在治疗的"}, {"probability": {"variance": 3.7e-05, "average": 0.997746, "min": 0.967398}, "location": {"width": 809, "top": 1012, "height": 34, "left": 206}, "words": "前48周内,另1名发生在第96周。该研究中没有发现其他导致对富马酸替诺福韦二"}, {"probability": {"variance": 1.2e-05, "average": 0.996933, "min": 0.990315}, "location": {"width": 178, "top": 1055, "height": 27, "left": 206}, "words": "吡呋酯耐药的突变"}, {"probability": {"variance": 0.00623, "average": 0.975609, "min": 0.584064}, "location": {"width": 811, "top": 1094, "height": 48, "left": 249}, "words": "在对未经治疗的受试者进行的研究934中(富马酸替诺福韦二吡呋酯+恩曲他滨+"}, {"probability": {"variance": 0.000699, "average": 0.987492, "min": 0.885756}, "location": {"width": 825, "top": 1139, "height": 35, "left": 205}, "words": "依非韦伦与齐多夫定拉米夫定+依非韦伦),对所有在第144周HIV-1RNA>400拷"}, {"probability": {"variance": 0.001015, "average": 0.99052, "min": 0.824704}, "location": {"width": 809, "top": 1182, "height": 33, "left": 207}, "words": "贝/mL确认病毒学应答失败的或提前终止治疗的受试者中分离出的HIV1进行了基因"}, {"probability": {"variance": 1.6e-05, "average": 0.998437, "min": 0.976862}, "location": {"width": 815, "top": 1224, "height": 33, "left": 206}, "words": "型分析。结果显示出现依非韦伦耐药相关的突变最为常见,两个治疗组中相似。在所"}, {"probability": {"variance": 0.000181, "average": 0.994265, "min": 0.944016}, "location": {"width": 800, "top": 1267, "height": 30, "left": 206}, "words": "分析的受试者分离病毒株中,与恩曲他滨和拉米夫定耐药有关的M184V突变在富马"}, {"probability": {"variance": 0.000271, "average": 0.993684, "min": 0.907644}, "location": {"width": 795, "top": 1307, "height": 33, "left": 205}, "words": "酸替诺福韦二吡呋酯+恩曲他滨组发生频率为219,在齐多夫定/拉米夫定组为10/29"}, {"probability": {"variance": 0.005534, "average": 0.980827, "min": 0.567218}, "location": {"width": 809, "top": 1350, "height": 32, "left": 206}, "words": "在持续144周的研究934中,使用标准的基因型分析,没有在受试者的HIV-1中检测"}, {"probability": {"variance": 0.0008, "average": 0.986278, "min": 0.917219}, "location": {"width": 132, "top": 1394, "height": 25, "left": 205}, "words": "到K65R突变"}, {"probability": {"variance": 0, "average": 0.973345, "min": 0.973345}, "location": {"width": 50, "top": 1462, "height": 48, "left": 1049}, "words": "它"}], "language": 3}